A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Talacotuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 23 Nov 2017 Planned End Date changed from 1 Feb 2019 to 26 Sep 2019.
- 23 Nov 2017 Planned initiation date changed from 1 Oct 2016 to 30 Jun 2017.
- 23 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.